The impact from LLS and C3 members is seen in the entire blood cancer patient journey.
Learn how together we're making a difference in the lives of patients.
Since 1949, we've invested more than $1 billion to become the leading funder of cutting-edge research and life-saving treatments.
Our investment has led to the development of nearly every therapy currently used to treat blood cancer - with many now being used to help patients with other cancers and chronic diseases.
Where survival rates for children with the most commonly diagnosed pediatric leukemia was once just 3%, today it's approximately 90%. In fact, thanks to years of extensive research and scientific support, survival rates for many blood cancers have doubled, tripled or even quadrupled.
OUR 50 PAGE 2017 REPORT
2017 was an unprecedented year for blood cancer breakthroughs with an extraordinary 18 blood cancer therapies approved by the FDA. LLS proudly played a role in the discovery and development of 15 of the 18.
Find out what else we've accomplished.